Nexalin Study Shows DIFS Technology Reduces Self-Injury and Depression in Adolescents

Event summary

  • Nexalin's DIFS™ technology showed statistically significant reductions in self-injury behaviors and depressive symptoms in female adolescents in a peer-reviewed study published in BMC Psychiatry on April 9, 2026.
  • The study involved six female adolescent patients who received 21 days of 77.5 Hz, 15 mA stimulation using a Nexalin device, with benefits persisting through follow-up assessments.
  • Key findings included significant improvements in HAMD-24 depression scores, OSIC self-injury scores, and measurable changes in brain-network activity and connectivity.
  • All patients met the study’s predefined clinical response criterion for depression, and 83.3% met the response criterion for self-injury outcomes.
  • Nexalin's DIFS technology is approved in China, Brazil, Oman, and Israel.

The big picture

Nexalin's study adds to a growing body of evidence supporting its DIFS technology as a non-invasive, drug-free approach for treating mental health disorders. The findings are particularly significant for addressing non-suicidal self-injury (NSSI) in adolescents, a challenging and urgent population. The company's strategy of pairing clinical outcomes with objective neurophysiological measures positions it to challenge the status quo in neurostimulation, potentially broadening its relevance across multiple CNS indications.

What we're watching

Clinical Validation
Whether Nexalin can replicate these results in larger, randomized controlled trials to solidify its technology's efficacy.
Regulatory Pathway
The pace at which Nexalin advances its regulatory approvals, particularly in the U.S., to broaden its market reach.
Market Differentiation
How Nexalin's high-power, non-invasive DIFS technology will compete against existing neurostimulation alternatives in the mental health space.

Related topics

Biotechnology